The first patient was enrolled at Yale School of Medicine’s Department of Psychiatry, marking a significant milestone in the trial.

Dr. Weikang Tao, the global R&D head of Qilu Pharmaceutical commented: “We greatly appreciate the collaboration, efforts and support of both Arbutus and Qilu's project teams for the development of ...